Developer docs
API playgroundTry for free, no card

Search company profiles

Sanjivani Parenteral

Full company profile

uuid003lt61

Namestring
Sanjivani Parenteral
Legal namestring
Sanjivani Paranteral Ltd.
Websiteurl
sanjivani.co.in
Company typeenum
Public
Founded yearint
2023
Descriptiontext

Sanjivani Parenteral (legal name: Sanjivani Paranteral Ltd.) is a publicly listed Indian pharmaceutical company headquartered in Mumbai, Maharashtra, that manufactures and supplies pharmaceutical formulations with a focus on parenteral (injectable) medicines and oral solids. The firm operates across manufacturing, research and development, domestic sales, and export functions, with a stated capability to accommodate both small and large volume orders and to deliver customized formulation solutions to client specifications. Its operating geographies cover India (domestic) and Bolivia (export), and it is listed on the Bombay Stock Exchange under ticker bom:531569.

The company's go-to-market is B2B contract manufacturing and supply of pharmaceutical formulations, serving other pharmaceutical companies (such as Macleods Pharmaceuticals Limited, with which it has maintained a partnership for over 10 years) and healthcare providers. Pricing is provided on a per-inquiry basis and not publicly disclosed, consistent with project-based B2B contract negotiations. The company emphasizes a value proposition built on competitive pricing, speed of delivery, flexible and responsive service, quality control testing, adherence to regulatory and ethical standards, and seamless technical transfer processes.

The firm has a small headcount (11-50 employees as disclosed) and is led by Managing Director Ashwani Khemka, who increased his shareholding to 29.88% via open market purchases disclosed to BSE in June 2026 in compliance with SEBI takeover regulations. No patents, trademarks, certifications, AI/ML capabilities, M&A activity, or external funding rounds are documented in the available data, indicating a lean, operations-focused operating model centered on manufacturing execution and customer relationships rather than technology differentiation.

Short descriptiontext

Sanjivani Parenteral is a Mumbai-based, publicly listed Indian pharmaceutical company that manufactures injectable and oral solid formulations for B2B contract supply to other pharmaceutical companies and healthcare providers, with operations spanning India and Bolivia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMumbai, India
HQ citystring
Mumbai
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, injectable medicines, oral solid dosage, parenteral formulations, contract manufacturing
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
Product category
Pharmaceutical Manufacturing
Social media profiles1 record
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sanjivani Parenteral is a pharmaceutical company that manufactures and supplies oral solid dosage forms and injectable (parenteral) formulations. The company operates across both domestic (India) and export markets, with capabilities spanning manufacturing, R&D, quality control testing, technical transfers, and supply chain operations. It accommodates both small and large volume orders with customized solutions tailored to specific customer requirements.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sanjivani Paranteral Ltd is a pharmaceutical company that manufactures and delivers high-quality medicines. The company operates across both domestic and export markets, with core offerings centered on pharmaceutical formulations. The product portfolio encompasses small and large volume pharmaceutical orders, with customized solutions tailored to specific customer requirements. The company emphasizes swift delivery, competitive pricing, streamlined supply chain operations, quality control, and regulatory compliance across its manufacturing and R&D capabilities.

Product and service1 record
1Parenteral (Injectable) Formulations
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
1Syngene International
TypeBroad incumbent
Description

India's largest listed CRO/CDMO with end-to-end discovery, development, and manufacturing services. Comparable to Sanjivani as a domestic pharma services provider, but significantly larger and more diversified across biologics and small molecules.

2Suven Pharmaceuticals
TypeDirect peer
Description

Indian CDMO focused on active pharmaceutical ingredients and intermediates, with growing formulations presence. Comparable to Sanjivani as a domestic pharmaceutical contract manufacturer serving large pharma buyers.

3Macleods Pharmaceuticals
TypeDirect peer
Description

One of India's largest generic pharmaceutical manufacturers and an existing Sanjivani customer. Comparable because it operates in pharmaceutical formulations and is part of Sanjivani's addressable buyer base; also a relevant comparator for Indian pharma scale and capability.

4Ipca Laboratories
TypeDirect peer
Description

Indian pharmaceutical manufacturer producing formulations and APIs across therapeutic areas. Comparable to Sanjivani as a domestic generic/formulations manufacturer participating in the same customer and competitive landscape.

5Ajanta Pharma
TypeBroad incumbent
Description

Established Indian branded-generic pharmaceutical company with manufacturing and global exports. Comparable to Sanjivani as an Indian formulations manufacturer, though substantially larger and broader in geographic reach.

6Dishman Carbogen Amcis
TypeDirect peer
Description

Indian-listed CDMO with global facilities providing API and drug product services. Comparable to Sanjivani as a contracted services provider to large pharma; contrasts by scale and regulatory reach.

7Hikal Limited
TypeDirect peer
Description

Indian CRAMS/CDMO serving global pharma and agrochemical customers with manufacturing capabilities. Comparable to Sanjivani as a similarly-positioned Indian contract manufacturer in regulated intermediates and APIs.

8Unichem Laboratories
TypeDirect peer
Description

Indian pharmaceutical company focused on formulations and APIs with domestic and export markets. Comparable to Sanjivani as a mid-sized Indian pharma manufacturer with similar export orientation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sanjivani Parenteral

Pharmaceutical Manufacturingsanjivani.co.in

Sanjivani Parenteral is a Mumbai-based, publicly listed Indian pharmaceutical company that manufactures injectable and oral solid formulations for B2B contract supply to other pharmaceutical companies and healthcare providers, with operations spanning India and Bolivia.

What Sanjivani Parenteral does

Sanjivani Parenteral (legal name: Sanjivani Paranteral Ltd.) is a publicly listed Indian pharmaceutical company headquartered in Mumbai, Maharashtra, that manufactures and supplies pharmaceutical formulations with a focus on parenteral (injectable) medicines and oral solids. The firm operates across manufacturing, research and development, domestic sales, and export functions, with a stated capability to accommodate both small and large volume orders and to deliver customized formulation solutions to client specifications. Its operating geographies cover India (domestic) and Bolivia (export), and it is listed on the Bombay Stock Exchange under ticker bom:531569.

The company's go-to-market is B2B contract manufacturing and supply of pharmaceutical formulations, serving other pharmaceutical companies (such as Macleods Pharmaceuticals Limited, with which it has maintained a partnership for over 10 years) and healthcare providers. Pricing is provided on a per-inquiry basis and not publicly disclosed, consistent with project-based B2B contract negotiations. The company emphasizes a value proposition built on competitive pricing, speed of delivery, flexible and responsive service, quality control testing, adherence to regulatory and ethical standards, and seamless technical transfer processes.

The firm has a small headcount (11-50 employees as disclosed) and is led by Managing Director Ashwani Khemka, who increased his shareholding to 29.88% via open market purchases disclosed to BSE in June 2026 in compliance with SEBI takeover regulations. No patents, trademarks, certifications, AI/ML capabilities, M&A activity, or external funding rounds are documented in the available data, indicating a lean, operations-focused operating model centered on manufacturing execution and customer relationships rather than technology differentiation.

Sanjivani Parenteral firmographics

Firmographics
Name
Sanjivani Parenteral
Legal name
Sanjivani Paranteral Ltd.
Website
https://sanjivani.co.in
Company type
Public
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Sanjivani Parenteral is a Mumbai-based, publicly listed Indian pharmaceutical company that manufactures injectable and oral solid formulations for B2B contract supply to other pharmaceutical companies and healthcare providers, with operations spanning India and Bolivia.
Ownership category
akta.pro rank

Where Sanjivani Parenteral is headquartered

Location

Headquarters

HQ city
Mumbai
HQ country
India
HQ region
Asia

Offices1 record

Markets served

Sanjivani Parenteral business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales

Distribution channels1 record

Marketing channels2 records

Sanjivani Parenteral product offering

Product offering

Core offering

Sanjivani Parenteral is a pharmaceutical company that manufactures and supplies oral solid dosage forms and injectable (parenteral) formulations. The company operates across both domestic (India) and export markets, with capabilities spanning manufacturing, R&D, quality control testing, technical transfers, and supply chain operations. It accommodates both small and large volume orders with customized solutions tailored to specific customer requirements.

Product overview

Sanjivani Paranteral Ltd is a pharmaceutical company that manufactures and delivers high-quality medicines. The company operates across both domestic and export markets, with core offerings centered on pharmaceutical formulations. The product portfolio encompasses small and large volume pharmaceutical orders, with customized solutions tailored to specific customer requirements. The company emphasizes swift delivery, competitive pricing, streamlined supply chain operations, quality control, and regulatory compliance across its manufacturing and R&D capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

  • Parenteral (Injectable) Formulations

Companies that use Sanjivani Parenteral

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Sanjivani Parenteral technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Sanjivani Parenteral partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Sanjivani Parenteral competitors and assessment

Company assessment

Broad incumbents

  • Syngene International: India's largest listed CRO/CDMO with end-to-end discovery, development, and manufacturing services. Comparable to Sanjivani as a domestic pharma services provider, but significantly larger and more diversified across biologics and small molecules.
  • Ajanta Pharma: Established Indian branded-generic pharmaceutical company with manufacturing and global exports. Comparable to Sanjivani as an Indian formulations manufacturer, though substantially larger and broader in geographic reach.

Direct peers

  • Suven Pharmaceuticals: Indian CDMO focused on active pharmaceutical ingredients and intermediates, with growing formulations presence. Comparable to Sanjivani as a domestic pharmaceutical contract manufacturer serving large pharma buyers.
  • Macleods Pharmaceuticals: One of India's largest generic pharmaceutical manufacturers and an existing Sanjivani customer. Comparable because it operates in pharmaceutical formulations and is part of Sanjivani's addressable buyer base; also a relevant comparator for Indian pharma scale and capability.
  • Ipca Laboratories: Indian pharmaceutical manufacturer producing formulations and APIs across therapeutic areas. Comparable to Sanjivani as a domestic generic/formulations manufacturer participating in the same customer and competitive landscape.
  • Dishman Carbogen Amcis: Indian-listed CDMO with global facilities providing API and drug product services. Comparable to Sanjivani as a contracted services provider to large pharma; contrasts by scale and regulatory reach.
  • Hikal Limited: Indian CRAMS/CDMO serving global pharma and agrochemical customers with manufacturing capabilities. Comparable to Sanjivani as a similarly-positioned Indian contract manufacturer in regulated intermediates and APIs.
  • Unichem Laboratories: Indian pharmaceutical company focused on formulations and APIs with domestic and export markets. Comparable to Sanjivani as a mid-sized Indian pharma manufacturer with similar export orientation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Customer concentration

Sanjivani Parenteral social profiles

Digital presence

Sanjivani Parenteral financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sanjivani Parenteral leadership team

Management profile

Number of profiles

Profiles1 record

Sanjivani Parenteral funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sanjivani Parenteral M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanjivani Parenteral

What does Sanjivani Parenteral do?

Sanjivani Parenteral is a pharmaceutical company that manufactures and supplies oral solid dosage forms and injectable (parenteral) formulations. The company operates across both domestic (India) and export markets, with capabilities spanning manufacturing, R&D, quality control testing, technical transfers, and supply chain operations. It accommodates both small and large volume orders with customized solutions tailored to specific customer requirements.

Is Sanjivani Parenteral a public or private company?

Sanjivani Parenteral is a public company. It is classified as public and is currently operating.

When was Sanjivani Parenteral founded?

Sanjivani Parenteral was founded in 2023. It employs 11 to 50 people.

Where is Sanjivani Parenteral based?

Sanjivani Parenteral is headquartered in Mumbai, India, in the Asia region.

Who are Sanjivani Parenteral's main competitors?

Broad incumbents on record are Syngene International and Ajanta Pharma. Direct peers are Suven Pharmaceuticals, Macleods Pharmaceuticals, Ipca Laboratories, Dishman Carbogen Amcis, Hikal Limited and Unichem Laboratories.

Does Sanjivani Parenteral have an API?

No public API is recorded for Sanjivani Parenteral.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScanXSanjivani Paranteral schedules 32nd AGM for September 16Sanjivani Paranteral issued notice on August 24, 2026, scheduling its 32nd AGM for September 16, 2026, via video conferencing at 11:00 am, with e-voting from September 13 to 15. Shareholders on record as of September 9 will adopt FY26 audited financial statements and re-appoint Chairman Ashwani Khemka, who draws ₹12.5 lakh monthly and holds 36.32 lakh shares.The TribuneSanjivani Parenteral Limited Reports Q1 FY27 Results; EBITDA stood at ₹ 43.21 Mn with PAT at ₹ 24.91 MnSanjivani Parenteral Limited reported its Q1 FY27 financial results, showing a 33.81% year-over-year growth in total income to ₹239.90 Mn and a 61.04% increase in EBITDA to ₹43.21 Mn. The company achieved a net profit of ₹24.91 Mn with a margin of 10.38%, driven by strong export performance which accounted for over 90% of revenue. Management highlighted operational improvements and the gradual scale-up of its Pune IV fluid facility as key factors behind this positive start.Indian Economic ObserverSanjivani Parenteral Limited Reports Q1 FY27 Results; EBITDA stood at ₹ 43.21 Mn with PAT at ₹ 24.91 MnSanjivani Parenteral Limited reported strong Q1 FY27 financial results, recording a 33.81% year-over-year growth in total income to ₹239.90 Mn and a 43.94% increase in net profit to ₹24.91 Mn. The company highlighted significant operational improvements, including a 61.04% rise in EBITDA to ₹43.21 Mn and an expansion of EBITDA margins by 305 basis points to 18.01%, driven largely by robust export performance. Management noted that the Pune IV fluid facility is undergoing gradual scale-up while the core formulations business remains resilient.Ani NewsSanjivani Parenteral Limited Reports Q1 FY27 Results; EBITDA stood at ₹ 43.21 Mn with PAT at ₹ 24.91 MnSanjivani Parenteral Limited reported strong financial results for Q1 FY27, with total income rising 33.81% year-over-year to ₹239.90 Mn and net profit increasing 43.94% to ₹24.91 Mn. The company attributed this growth to improved operational efficiencies and a recovery in exports, which accounted for over 90% of its revenue.